Who We Are
Alexion is a global
biopharmaceutical company that discovers, develops and delivers life-changing therapies
for patients living with severe, life-threatening and often ultra-rare diseases. With fully
integrated scientific, medical, regulatory, manufacturing and commercial capabilities,
Alexion is well-positioned to meet the needs of patients today and in the future.
The company's first product, Soliris® (eculizumab), is a first-in-class terminal complement inhibitor.
Soliris is the first and only therapy approved for the treatment of paroxysmal nocturnal hemoglobinuria (PNH),
an ultra-rare, debilitating and life-threatening blood disorder defined by the destruction of red blood cells,
or hemolysis. Soliris is also the first and only therapy approved for the treatment of atypical hemolytic uremic
syndrome (aHUS), an ultra-rare, genetic and life-threatening disease in which blood clots throughout the body cause damage
to vital organs, including the kidneys, heart and brain.
Soliris is the first in a new class of therapies to inhibit terminal complement, a group of proteins involved in the body's
immune response. Extensive
clinical trials show that Soliris reduces hemolysis in patients with PNH,
leading to an improvement in symptoms and a reduction in major health problems associated
with this disease.
Alexion scientists, working closely with leading researchers and physicians worldwide,
are investigating
eculizumab as a potential treatment for patients with other debilitating
and ultra-rare diseases in which complement plays a role.
The Company is also developing a portfolio of four innovative drug candidates beyond eculizumab for the treatment
of additional severe and ultra-rare disorders.